Albert Lowe
Stock Analyst at Craig-Hallum
(4.24)
# 1,577
Out of 4,698 analysts
140
Total ratings
48.2%
Success rate
13.6%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $68 | $31.32 | +117.11% | 1 | Aug 20, 2026 | |
| SPRB Spruce Biosciences | Maintained: Buy | $140 | $57.93 | +141.67% | 2 | Aug 13, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintained: Buy | n/a | $1.08 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Maintained: Buy | n/a | $4.67 | - | 11 | Jul 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $157.24 | +30.37% | 6 | Jun 22, 2026 | |
| SABS SAB Biotherapeutics | Maintained: Buy | $6 | $3.72 | +61.29% | 10 | Jun 16, 2026 | |
| CRDF Cardiff Oncology | Downgraded: Hold | $2 | $1.09 | +83.49% | 13 | Jun 4, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 | $38.60 | +68.39% | 7 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $25 → $12 | $1.48 | +710.81% | 9 | May 12, 2026 | |
| CMPX Compass Therapeutics | Maintained: Buy | n/a | $2.38 | - | 6 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19.37 | $11.64 | +66.44% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.01 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.86 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $4.58 | -12.66% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.52 | +296.83% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.02 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $13.29 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.29 | +210.08% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.50 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $281.86 | n/a | 1 | Jun 4, 2024 |
Quince Therapeutics
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $68
Current: $31.32
Upside: +117.11%
Spruce Biosciences
Aug 13, 2026
Maintained: Buy
Price Target: $140
Current: $57.93
Upside: +141.67%
Lineage Cell Therapeutics
Jul 14, 2026
Maintained: Buy
Price Target: n/a
Current: $1.08
Upside: -
Opus Genetics
Jul 6, 2026
Maintained: Buy
Price Target: n/a
Current: $4.67
Upside: -
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $157.24
Upside: +30.37%
SAB Biotherapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $6
Current: $3.72
Upside: +61.29%
Cardiff Oncology
Jun 4, 2026
Downgraded: Hold
Price Target: $2
Current: $1.09
Upside: +83.49%
Neurogene
May 15, 2026
Maintained: Buy
Price Target: $65
Current: $38.60
Upside: +68.39%
Actuate Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $25 → $12
Current: $1.48
Upside: +710.81%
Compass Therapeutics
May 6, 2026
Maintained: Buy
Price Target: n/a
Current: $2.38
Upside: -
May 5, 2026
Reiterated: Buy
Price Target: $19.37
Current: $11.64
Upside: +66.44%
Apr 2, 2026
Maintained: Buy
Price Target: n/a
Current: $5.01
Upside: -
Mar 11, 2026
Maintained: Hold
Price Target: n/a
Current: $1.86
Upside: -
Feb 17, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $4.58
Upside: -12.66%
Feb 12, 2026
Maintained: Buy
Price Target: $10
Current: $2.52
Upside: +296.83%
Jan 23, 2026
Maintained: Buy
Price Target: n/a
Current: $3.02
Upside: -
Jan 12, 2026
Maintained: Buy
Price Target: n/a
Current: $13.29
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: $4
Current: $1.29
Upside: +210.08%
Jun 6, 2024
Maintained: Buy
Price Target: n/a
Current: $9.50
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $281.86
Upside: n/a